Tissue Selling General Administrative vs Other Operating Expenses Analysis
TRX Stock | 58.50 1.50 2.50% |
Tissue Regenix financial indicator trend analysis is much more than just breaking down Tissue Regenix Group prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tissue Regenix Group is a good investment. Please check the relationship between Tissue Regenix Selling General Administrative and its Other Operating Expenses accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tissue Regenix Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Selling General Administrative vs Other Operating Expenses
Selling General Administrative vs Other Operating Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tissue Regenix Group Selling General Administrative account and Other Operating Expenses. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Tissue Regenix's Selling General Administrative and Other Operating Expenses is 0.52. Overlapping area represents the amount of variation of Selling General Administrative that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of Tissue Regenix Group, assuming nothing else is changed. The correlation between historical values of Tissue Regenix's Selling General Administrative and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling General Administrative of Tissue Regenix Group are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Selling General Administrative i.e., Tissue Regenix's Selling General Administrative and Other Operating Expenses go up and down completely randomly.
Correlation Coefficient | 0.52 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Selling General Administrative
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Tissue Regenix Group. It is also known as Tissue Regenix overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most indicators from Tissue Regenix's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tissue Regenix Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tissue Regenix Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. As of January 7, 2025, Selling General Administrative is expected to decline to about 10.2 M. In addition to that, Tax Provision is expected to decline to about (14.5 K)
Tissue Regenix fundamental ratios Correlations
Click cells to compare fundamentals
Tissue Regenix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tissue Regenix fundamental ratios Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 36.7M | 34.1M | 38.3M | 43.2M | 49.7M | 30.2M | |
Total Stockholder Equity | 28.5M | 25.4M | 26.0M | 30.2M | 34.7M | 25.9M | |
Liabilities And Stockholders Equity | 36.7M | 34.1M | 38.3M | 43.2M | 49.7M | 30.3M | |
Other Stockholder Equity | 93.5M | 98.1M | 138.9M | 154.4M | 177.5M | 186.4M | |
Total Liab | 8.9M | 9.5M | 13.0M | 13.9M | 16.0M | 16.8M | |
Common Stock | 11.7M | 11.8M | 13.3M | 91K | 104.7K | 99.4K | |
Common Stock Shares Outstanding | 44.5M | 70.3M | 70.3M | 70.4M | 81.0M | 80.5M | |
Other Current Liab | 1.4M | 477.5K | 4.4M | 2.6M | 3.0M | 1.6M | |
Total Current Liabilities | 3.3M | 3.2M | 5.5M | 4.7M | 5.4M | 5.7M | |
Property Plant And Equipment Net | 5.7M | 6.7M | 7.4M | 9.0M | 10.4M | 10.9M | |
Net Debt | (4.2M) | 175.7K | 3.0M | 4.7M | 5.5M | 5.7M | |
Retained Earnings | (77.7M) | (84.7M) | (96.8M) | (123.8M) | (111.4M) | (105.8M) | |
Accounts Payable | 1.3M | 2.6M | 1.1M | 1.2M | 1.4M | 921.0K | |
Cash | 9.6M | 5.7M | 4.9M | 4.7M | 4.2M | 4.0M | |
Non Current Assets Total | 16.6M | 17.8M | 20.0M | 24.2M | 27.8M | 29.2M | |
Non Currrent Assets Other | (8.6M) | (8.6M) | (9.6M) | (5.2M) | (6.0M) | (6.3M) | |
Cash And Short Term Investments | 9.6M | 5.7M | 4.9M | 4.7M | 4.2M | 4.0M | |
Net Receivables | 3.5M | 3.4M | 4.3M | 2.4M | 2.7M | 2.1M | |
Good Will | 8.6M | 8.6M | 9.6M | 11.6M | 10.4M | 9.1M | |
Non Current Liabilities Total | 5.6M | 6.3M | 7.5M | 9.2M | 10.5M | 11.1M | |
Other Current Assets | 1.7M | 1.2M | 834.7K | 4.1M | 4.7M | 4.9M | |
Property Plant And Equipment Gross | 5.7M | 9.1M | 8.9M | 14.4M | 16.6M | 17.4M | |
Total Current Assets | 20.1M | 16.3M | 18.3M | 19.1M | 22.0M | 20.8M | |
Accumulated Other Comprehensive Income | 955K | 197.9K | (942.7K) | (529.5K) | (608.9K) | (639.4K) | |
Intangible Assets | 10.9M | 11.1M | 12.5M | 3.5M | 4.1M | 3.9M | |
Property Plant Equipment | 2.4M | 5.7M | 9.1M | 8.9M | 10.3M | 10.8M | |
Net Tangible Assets | 7.2M | 17.7M | 19.3M | 17.6M | 20.2M | 17.7M | |
Inventory | 7.1M | 7.2M | 9.0M | 10.4M | 11.9M | 12.5M | |
Other Liab | 670K | 560K | 640K | 520K | 468K | 618.7K | |
Net Invested Capital | 31.3M | 38.8M | 37.5M | 36.1M | 41.6M | 38.4M | |
Net Working Capital | 16.8M | 17.7M | 15.4M | 14.4M | 16.5M | 15.8M | |
Capital Stock | 9.6M | 9.2M | 9.2M | 91K | 81.9K | 77.8K | |
Short Long Term Debt Total | 5.3M | 5.9M | 8.0M | 9.4M | 10.8M | 6.8M | |
Long Term Debt | 2.8M | 4.5M | 5.3M | 5.5M | 6.4M | 4.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.BTC | Bitcoin | |
TRX | TRON | |
BNB | Binance Coin |
Other Information on Investing in Tissue Stock
Balance Sheet is a snapshot of the financial position of Tissue Regenix Group at a specified time, usually calculated after every quarter, six months, or one year. Tissue Regenix Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Tissue Regenix and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Tissue currently owns. An asset can also be divided into two categories, current and non-current.